DAN-RSV: RSVpreF Vaccine for Preventing Cardiorespiratory Hospitalizations
Description
The DAN-RSV trial is one of the largest individually randomized studies ever conducted, enrolling over 131,000 participants aged 60 and older to evaluate the effectiveness of the RSVpreF vaccine. Using a pragmatic design with electronic consent and national health registry data, the trial successfully met its primary objective of reducing RSV-related respiratory tract disease hospitalizations. It also achieved all key secondary endpoints, showing favorable outcomes for RSV-related and all-cause respiratory and cardiorespiratory hospitalizations. These results demonstrate the vaccine’s potential to significantly impact public health and inform future RSV vaccine policy.
In this interview, Drs. Richard A. Chazal and Tor Biering-Sørensen discuss “DAN-RSV: RSVpreF Vaccine for Preventing Cardiorespiratory Hospitalizations.”
Suggested Materials:
-
Tor Biering-Sørensen (2025). Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Older Adults (DAN-RSV) (ClinicalTrials.gov Identifier NCT06684743). Retrieved from https://clinicaltrials.gov/study/NCT06684743.
Subscribe on Apple Podcasts | Subscribe to ACCEL
United States
